Clinical Trials Logo

Clinical Trial Summary

The goal of this prospective, multi-center, randomized, controlled study is to compare the safety and efficacy of the ProtEmbo Cerebral Embolic Protection device to a hybrid control (no embolic protection device ('No Device') and the Sentinel device) in subjects with severe symptomatic native aortic valve stenosis indicated undergoing a TAVR procedure.


Clinical Trial Description

Subjects with severe symptomatic aortic stenosis undergoing TAVR will be able to participate. Participants will be randomized in a 2:1:1 fashion to either the ProtEmbo arm, the Sentinel arm, or the 'No device' arm. Enrolled subjects will undergo an MRI at baseline and at 36 hours ±12 hours, to evaluate any new cerebral lesions. Enrolled subjects will be followed for 30 days. The study aims to address: - whether the occurrence of all Major Adverse Cardiac and Cerebrovascular Events (MACCE) at 30 days is comparable between the ProtEmbo group and the hybrid control group. - whether the total new lesion volume in the brain assessed by diffusion weighted magnetic resonance images at 36 ±12 hours is comparable between the ProtEmbo group and the hybrid control group. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05873816
Study type Interventional
Source Protembis GmbH
Contact Nawzer Mehta, PhD
Phone +1 707 293 5435
Email nm@protembis.com
Status Recruiting
Phase N/A
Start date March 21, 2024
Completion date July 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05552352 - VRAP-Heart - Virtual Reality Assisted Patient Empowerment for Interventions in Structural Heart Disease N/A
Recruiting NCT06168123 - Future Optimal Research and Care Evaluation - Aortic Stenosis
Active, not recruiting NCT05182307 - DurAVRâ„¢ THV System: First-In-Human Study N/A
Recruiting NCT06156592 - Post Spinal Hemodynamic Changes in Aortic Stenosis and Mitral Regurgitation by VIS Index and Echocardiography
Completed NCT04259723 - Virtual Reality Assisted Conscious Sedation During TAVI N/A
Recruiting NCT04128384 - Infranodal Conduction Time During TAVR as Predictor of HAVB N/A
Recruiting NCT05024942 - LUS in Aortic Stenosis Patients Undergoing TAVR
Recruiting NCT05283356 - Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation Phase 4
Not yet recruiting NCT05847751 - The Use of ACURATE Neo 2 Valve in Patients With Symptomatic Aortic Valve Stenosis
Completed NCT02224066 - Platelet Reactivity After TAVI: A Multicenter Pilot Study Phase 4
Recruiting NCT06168370 - Personalized, CT-guided Antithrombotic Therapy Versus Lifelong Single Antiplatelet Therapy to Reduce Thromboembolic and Bleeding Events in Non-atrial Fibrillation Patients After Transcatheter Aortic Valve Implantation N/A
Recruiting NCT05097183 - Validation of Accurate Commissural Alignment During Transcatheter Aortic Valve Implantation
Active, not recruiting NCT05712161 - Use of DurAVRâ„¢ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study N/A
Not yet recruiting NCT04988243 - Multi Center Registry of Transcatheter Aortic Valve Replacement in Northeast China N/A